Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Companies Resolve Lawsuit in DelawareBOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra’s serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have reached a mutually beneficial agreement with Commave regardin ...